SafePeptides.org is your trusted, independent resource for accurate, research-grounded information on peptides — their science, safety profiles, and responsible use.
Our Mission
SafePeptides.org was founded on a simple belief: people deserve access to clear, accurate, unbiased information about peptides — without the noise of marketing or misinformation.
We synthesize peer-reviewed research, clinical literature, and expert opinion into digestible, honest overviews. Whether you're a healthcare professional, researcher, or informed individual, this is your starting point.
We have no affiliations with peptide vendors or pharmaceutical companies. Our only agenda is accuracy.
Every claim is sourced from peer-reviewed literature and clinical data.
We prioritize honest safety profiles over hype or performance claims.
No vendor affiliations. No sponsored content. No conflicts of interest.
We continuously revise entries as new research emerges.
Peptide Library
Educational profiles on 130+ researched peptides. Search by name or filter by category below.
Showing 130 peptides
A phosphopeptide derived from IRS-1 protein that activates PI3K signaling. Studied in preclinical models for its role in insulin-like metabolic and proliferative pathways.
A selective Mas receptor antagonist used to block angiotensin-(1-7) signaling. Widely used as a research tool to study the protective arm of the renin-angiotensin system.
A fragment of adrenocorticotropic hormone studied for cognitive enhancement, neuroprotection, and attention modulation without significant adrenal activity.
A pro-apoptotic peptide that selectively targets blood vessels feeding white adipose tissue. Preclinical research has shown significant fat mass reduction in animal models.
A synthetic GnRH agonist used in reproductive endocrinology research, studied for its ability to stimulate LH and FSH release and manage hormone-dependent conditions.
A naturally occurring peptide from blow fly hemolymph with antiviral and immunomodulatory properties. Researched for interferon-inducing activity in early infection models.
A thymic peptide studied for immunomodulatory properties, particularly in restoring immune competence in immunodeficient research models.
A bioactive heptapeptide of the renin-angiotensin system with vasodilatory, anti-inflammatory, and anti-fibrotic effects — the counter-regulatory arm to Angiotensin II.
The primary effector peptide of the renin-angiotensin system. A potent vasoconstrictor widely studied in hypertension, cardiac remodeling, and fluid balance research.
A potent GnRH antagonist developed for suppression of LH and FSH surges. Used in reproductive medicine research and studies involving hormone-dependent tumors.
A modified C-terminal fragment of human growth hormone (hGH177-191) studied for lipolytic activity without the anabolic or diabetogenic effects associated with full hGH.
Synthetic vasopressin (AVP) acting on V1 and V2 receptors. Studied in diabetes insipidus, septic shock hemodynamics, and central nervous system signaling.
Synthetic vasoactive intestinal peptide (VIP) with potent vasodilatory and anti-inflammatory properties. Researched in pulmonary arterial hypertension and respiratory distress.
A pentadecapeptide derived from human gastric juice with broad cytoprotective and regenerative properties. One of the most extensively studied peptides in preclinical healing research.
A synthetic melanocortin receptor agonist originally studied for tanning. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
A first-in-class entry inhibitor that blocks hepatitis B and D viral entry into hepatocytes via the NTCP receptor. EMA-approved for chronic hepatitis D treatment.
A synthetic GnRH agonist used clinically for prostate cancer, endometriosis, and fertility. Acts via desensitization of pituitary GnRH receptors with continuous use.
A long-acting amylin analog under clinical investigation in combination with semaglutide (CagriSema) for obesity treatment, targeting dual hormonal pathways for weight reduction.
A naturally occurring dipeptide (beta-alanyl-L-histidine) with antioxidant, anti-glycation, and neuroprotective properties. Studied in aging, exercise physiology, and neurodegeneration.
Recombinant human atrial natriuretic peptide (hANP) used clinically in Japan for acute decompensated heart failure. Promotes natriuresis, diuresis, and vasodilation.
A cell-permeable peptide that selectively inhibits caspase-9, blocking the intrinsic apoptotic pathway. Used as a research tool to study programmed cell death mechanisms.
The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial, immunomodulatory, and wound-healing properties. Key to mucosal immunity research.
A cyclic RGD pentapeptide that inhibits integrin αvβ3 and αvβ5, disrupting tumor angiogenesis. Studied extensively in glioblastoma and other solid tumor trials.
A synthetic GHRH analog with extended half-life via albumin binding. Studied for sustained stimulation of growth hormone and IGF-1 secretion over days to weeks.
CJC-1295 conjugated with a Drug Affinity Complex (DAC) for prolonged albumin binding, resulting in a significantly extended half-life compared to the non-DAC version.
A synthetic Leu-enkephalin analog with opioid receptor activity. Studied for gastroprotective, analgesic, and cytoprotective effects in preclinical and early clinical research.
A GnRH receptor antagonist used clinically for prostate cancer. Unlike agonists, it causes immediate testosterone suppression without initial hormone flare. Approved as Firmagon.
A potent hepatocyte growth factor (HGF) potentiator that crosses the blood-brain barrier. Preclinical research suggests enhancement of synaptogenesis and cognitive function.
A potent GnRH superagonist used in veterinary medicine and studied in human reproductive research for controlled ovarian hyperstimulation and precocious puberty management.
A synthetic analog of vasopressin with selective V2 receptor activity. Clinically used for central diabetes insipidus, primary nocturnal enuresis, and hemostatic disorders.
A peripherally restricted kappa-opioid receptor agonist. FDA-approved for CKD-associated pruritus, with research interest in pain and itch modulation without CNS side effects.
A plasma kallikrein inhibitor studied for on-demand treatment of hereditary angioedema attacks, targeting the contact activation pathway of the kinin system.
Delta sleep-inducing peptide, a neuropeptide originally isolated from rabbit brain. Studied for sleep architecture normalization, stress modulation, and neuroendocrine regulation.
A radiolabeled somatostatin analog (DOTATOC) used in peptide receptor radionuclide therapy and PET imaging of neuroendocrine tumors expressing somatostatin receptors.
A mitochondria-targeting tetrapeptide that binds cardiolipin on the inner mitochondrial membrane. Studied for cardioprotection, renal protection, and mitochondrial dysfunction diseases.
A tetrapeptide studied for neuroprotective and anxiolytic properties, with research interest in delta sleep modulation and neurological stress response pathways.
A 36-amino acid HIV fusion inhibitor that blocks viral entry by preventing gp41 conformational changes. FDA-approved as Fuzeon for treatment-experienced HIV patients.
An oral PCSK9 inhibitor peptide in late-stage trials for LDL cholesterol reduction. A novel macrocyclic peptide approach to cardiovascular risk management.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland. Studied for telomerase activation, telomere elongation, and anti-aging biological effects.
A cyclic heptapeptide GPIIb/IIIa inhibitor used clinically to prevent platelet aggregation during acute coronary syndrome and percutaneous coronary intervention.
A synthetic calcimimetic peptide (calcium-sensing receptor agonist) approved for secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.
A GLP-1 receptor agonist originally derived from Gila monster venom. FDA-approved for type 2 diabetes and studied for weight loss and neuroprotective effects.
A synthetic vasopressin analog used primarily as a vasoconstrictor in local anesthetics. Studied as an alternative to epinephrine in dental and surgical settings.
A synthetic GnRH analog used in veterinary reproductive management and studied in human fertility protocols for triggering ovulation and LH surge induction.
An RNA interference therapeutic targeting antithrombin, studied in hemophilia A and B to reduce bleeding episodes by restoring thrombin generation via RNAi.
A D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells, selectively inducing apoptosis in senescent cells while sparing healthy tissue.
A potent GnRH receptor antagonist used in controlled ovarian stimulation protocols. Rapidly suppresses LH surges without the initial flare seen with GnRH agonists.
A naturally occurring copper-binding tripeptide (Gly-His-Lys) with wound healing, anti-inflammatory, and collagen-stimulating properties. Widely studied in dermatology and tissue repair.
A synthetic hexapeptide growth hormone secretagogue that stimulates GH release via the ghrelin receptor. More potent than GHRP-6 with less pronounced appetite stimulation.
One of the first synthetic GH secretagogues. Stimulates GH release through ghrelin receptor agonism and is associated with significant appetite stimulation and IGF-1 elevation.
An RNAi therapeutic targeting ALAS1, approved for acute hepatic porphyria. Reduces neurotoxic heme precursors by silencing the rate-limiting enzyme in heme biosynthesis.
A synthetic mixture of random polypeptides resembling myelin basic protein, approved for relapsing-remitting multiple sclerosis via immune deviation and neuroprotective mechanisms.
A long-acting GLP-2 receptor agonist investigated for short bowel syndrome, promoting intestinal adaptation and mucosal growth to reduce parenteral nutrition dependence.
A 29-amino acid pancreatic hormone that raises blood glucose through hepatic glycogenolysis and gluconeogenesis. Critical in hypoglycemia management and metabolic homeostasis research.
Synthetic GnRH identical to the endogenous form. Used in fertility diagnostics and treatment to stimulate pituitary LH and FSH secretion in a pulsatile manner.
A GnRH superagonist approved for prostate cancer, breast cancer, and endometriosis. Induces chemical castration via pituitary desensitization after an initial hormone flare.
A spider venom-derived peptide inhibitor of mechanosensitive ion channels (Piezo1, TRPC). Used in cardiac arrhythmia and mechanobiology research as a selective tool compound.
A synthetic peptide analog of α-MSH studied for melanogenesis modulation. Researched for skin pigmentation applications and potential tanning effects with improved safety.
A potent synthetic hexapeptide GH secretagogue. Shows strong GH release and direct cardioprotective effects via CD36 receptor activity independent of growth hormone.
A potent GnRH superagonist delivered via subcutaneous implant for precocious puberty and advanced prostate cancer. FDA-approved as Supprelin LA and Vantas.
A selective bradykinin B2 receptor antagonist approved for acute hereditary angioedema. Blocks the kinin-kallikrein pathway to rapidly reduce vascular permeability and swelling.
A long-acting IGF-1 analog with reduced binding protein affinity, resulting in an extended half-life. Studied for muscle growth, tissue repair, and anabolic signaling.
An siRNA therapeutic targeting PCSK9 mRNA in hepatocytes, approved for LDL cholesterol reduction in high-risk cardiovascular patients. Administered just twice yearly.
A selective, clean GH secretagogue with minimal effect on cortisol, prolactin, or ACTH. Widely studied for its favorable safety profile in growth hormone stimulation research.
A neuropeptide that activates GnRH neurons via the KISS1R receptor, acting as a master regulator of the reproductive axis. Studied in fertility disorders and puberty.
A C-terminal tripeptide fragment of α-MSH (Lys-Pro-Val) with anti-inflammatory properties. Studied for gut inflammation, wound healing, and skin disorders via melanocortin signaling.
A long-acting somatostatin analog approved for acromegaly and gastroenteropancreatic neuroendocrine tumors. Inhibits GH, IGF-1, and tumor-related peptide secretion.
A GnRH agonist approved for prostate cancer, endometriosis, and precocious puberty. Sustained-release formulations enable monthly or quarterly depot administration.
A guanylate cyclase-C agonist approved for IBS-C and chronic idiopathic constipation. Acts locally in the intestine to accelerate GI transit and reduce visceral pain.
A GLP-1 receptor agonist approved for type 2 diabetes and obesity. Reduces appetite, slows gastric emptying, and has demonstrated cardiovascular protective effects in trials.
A short-acting GLP-1 receptor agonist approved for type 2 diabetes. Its rapid action preferentially blunts postprandial glucose spikes by slowing gastric emptying.
The human cathelicidin antimicrobial peptide with broad-spectrum activity against bacteria, fungi, and viruses. Also plays roles in immune modulation, angiogenesis, and wound repair.
A soy-derived 43-amino acid peptide with epigenetic regulatory activity. Studied for cancer prevention, anti-inflammatory effects, and cholesterol-lowering properties.
A lysine vasopressin analog used historically for diabetes insipidus management. Acts on renal V2 receptors to promote water reabsorption and reduce urine output.
A dual GLP-1/glucagon receptor agonist in development for obesity and NAFLD. The glucagon component augments energy expenditure beyond GLP-1 alone for complementary metabolic benefits.
A linear synthetic analog of α-MSH that stimulates melanogenesis via MC1R. Studied for photoprotection and tanning effects with a longer half-life than natural α-MSH.
A cyclic lactam analog of α-MSH active at MC1R, MC3R, MC4R, and MC5R. Associated with tanning, sexual arousal, and appetite suppression. Carries notable safety considerations.
A synthetic peptide that mimics α-MSH activity to stimulate melanocyte pigmentation without UV exposure. Used in cosmetic research for even skin tone and photoprotection.
The primary bioactive component of honey bee venom with potent membrane-disrupting properties. Studied for antimicrobial, anti-cancer, and anti-parasitic applications despite significant cytotoxicity.
A potent, long-acting CXCR4 antagonist approved for hematopoietic stem cell mobilization in combination with G-CSF for enhanced harvest in multiple myeloma patients.
A mitochondria-derived peptide encoded in the 12S rRNA that regulates metabolic homeostasis via AMPK activation. Studied for insulin sensitivity, exercise mimicry, and aging.
A potent GnRH superagonist administered nasally for endometriosis and central precocious puberty. Induces pituitary downregulation with continuous use to reduce sex steroid production.
Recombinant B-type natriuretic peptide (BNP) approved for acutely decompensated heart failure. Promotes vasodilation, natriuresis, and diuresis via cGMP-mediated pathways.
A long-acting somatostatin analog approved for acromegaly, carcinoid syndrome, and VIPomas. Widely used in neuroendocrine tumor management and upper GI hemorrhage control.
An endogenous human pentapeptide that inhibits enkephalin-degrading enzymes, potentiating natural opioid activity. Studied for pain modulation and depression without direct receptor binding.
An oral non-peptide GLP-1 receptor agonist in late-stage development for type 2 diabetes and obesity. Offers the potential of once-daily oral dosing without injection requirements.
The nonapeptide "bonding hormone" produced in the hypothalamus. Studied for roles in social bonding, parturition, lactation, anxiety modulation, and autism spectrum disorder research.
A PEGylated parathyroid hormone analog approved for hypoparathyroidism. Provides sustained PTH activity with once-daily dosing for physiological calcium and phosphate regulation.
A multi-receptor somatostatin analog with high affinity for SST1–SST5. Approved for Cushing's disease and acromegaly refractory to first-generation somatostatin analogs.
A PEGylated cyclic peptide targeting complement protein C3, approved for paroxysmal nocturnal hemoglobinuria and geographic atrophy. Broadly inhibits complement-mediated hemolysis.
A naturally occurring pentapeptide inhibitor of aspartyl proteases (pepsin, cathepsin D). Widely used as a research tool to study protease-dependent pathways in disease models.
A guanylate cyclase-C agonist structurally related to uroguanylin, approved for chronic idiopathic constipation and IBS-C. Regulates intestinal fluid secretion locally in the lumen.
An RNAi therapeutic targeting APOC3 mRNA to reduce triglyceride-rich lipoproteins. In trials for familial chylomicronemia syndrome and severe hypertriglyceridemia.
A synthetic amylin analog approved as an adjunct to insulin therapy. Suppresses post-meal glucagon, slows gastric emptying, and reduces food intake in both T1D and T2D.
Synthetic thyrotropin-releasing hormone (TRH) used diagnostically to assess pituitary-thyroid axis function. Also studied for respiratory stimulation and neurological applications.
A melanocortin receptor agonist originally developed from Melanotan II. FDA-approved as Vyleesi for female hypoactive sexual desire disorder; studied in men for erectile dysfunction.
A triple GIP/GLP-1/glucagon receptor agonist in late-stage development for obesity. Phase 2 data showed up to 24% body weight reduction, among the highest reported for any agent.
A synthetic hepcidin mimetic studied for polycythemia vera. Regulates iron availability and red blood cell production by mimicking the endogenous iron-regulatory hormone hepcidin.
An octapeptide that competes with SNAP-25 for SNARE complex formation, partially inhibiting neuromuscular junction signaling. Studied as a topical alternative to botulinum toxin.
A synthetic heptapeptide analog of ACTH(4-7) developed in Russia. Studied for cognitive enhancement, neuroprotection, BDNF upregulation, and post-stroke recovery applications.
A 27-amino acid gastrointestinal hormone that stimulates pancreatic bicarbonate secretion. Used diagnostically for Zollinger-Ellison syndrome and pancreatic exocrine function assessment.
A synthetic heptapeptide analog of tuftsin with anxiolytic and nootropic properties. Studied for reducing anxiety without sedation and enhancing memory consolidation.
A GLP-1 receptor agonist approved for type 2 diabetes and obesity (Ozempic/Wegovy). Demonstrates significant cardiovascular risk reduction and is under study for NASH and neurodegeneration.
A melanocortin-4 receptor agonist approved for obesity caused by LEPR, POMC, or PCSK1 deficiency. Restores leptin pathway signaling to normalize appetite and body weight.
A synthetic analog of the first 29 amino acids of GHRH that stimulates pituitary GH secretion. Studied as an anti-aging, body composition, and sleep quality intervention.
Synthetic C-terminal octapeptide of cholecystokinin (CCK-8) used to stimulate gallbladder contraction for hepatobiliary imaging and pancreatic exocrine function assessment.
An endogenous cyclic tetradecapeptide that inhibits GH, insulin, glucagon, and multiple GI peptides. Used clinically for acute variceal bleeding and in neuroendocrine research.
A dual glucagon/GLP-1 receptor agonist in clinical trials for obesity and NASH. The glucagon component drives hepatic fat oxidation and energy expenditure beyond GLP-1 effects alone.
A synthetic fragment of thymosin beta-4 (Ac-SDKP). Studied for promoting actin polymerization, accelerating tissue repair, reducing inflammation, and enhancing wound healing.
Recombinant PTH(1-34) approved for osteoporosis in high-fracture-risk patients. The only approved anabolic bone agent that stimulates new bone formation rather than just preventing resorption.
A synthetic vasopressin analog with preferential V1 receptor activity. Used for hepatorenal syndrome and variceal bleeding; studied as an alternative to norepinephrine in septic shock.
A stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy. Reduces visceral adipose tissue through physiological GH stimulation while maintaining IGF-1 within normal ranges.
A synthetic 24-amino acid peptide corresponding to the active N-terminal of ACTH. Used diagnostically to assess adrenal cortex responsiveness and therapeutically in inflammatory conditions.
A thymic peptide that enhances T-cell function and innate immunity. Approved in multiple countries for hepatitis B, hepatitis C, and as an immune adjuvant in cancer and sepsis.
A synthetic pentapeptide corresponding to the active site of thymopoietin. Studied for immunomodulatory effects in autoimmune disease, aging-related immune decline, and infection.
A 43-amino acid peptide that sequesters G-actin and promotes cell migration, wound healing, angiogenesis, and anti-inflammatory responses. Widely studied in cardiac and tissue repair models.
The N-terminal tetrapeptide fragment of thymosin beta-4 (Ac-SDKP). Retains significant anti-inflammatory and tissue repair activity as a more accessible fragment of the parent peptide.
A zinc-dependent thymic nonapeptide essential for T-lymphocyte differentiation and maturation. Studied in immunodeficiency, autoimmunity, and age-related thymic involution research.
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity (Mounjaro/Zepbound). Clinical trials showed weight reductions up to 22%, representing a new class of metabolic therapy.
A class of short peptides engineered with cell-penetrating or skin-penetrating sequences to enhance transdermal delivery of active compounds for cosmetic and therapeutic applications.
A GnRH agonist approved for prostate cancer, endometriosis, precocious puberty, and gender dysphoria. Delivered as a sustained-release depot for monthly or quarterly administration.
A synthetic analog of IGF-1's tripeptide core (GPE), approved for Rett syndrome. Reduces neuroinflammation and synaptic dysfunction through glial and neuronal mechanisms.
A synthetic octapeptide somatostatin analog used for acute variceal hemorrhage. Inhibits splanchnic vasodilation and portal hypertension through somatostatin receptor binding.
The endogenous antidiuretic hormone regulating water reabsorption and blood pressure. Used clinically in vasodilatory shock, cardiac arrest, and central diabetes insipidus management.
A synthetic cone snail peptide (ω-conotoxin MVIIA) that blocks N-type calcium channels. FDA-approved as Prialt for severe chronic pain via intrathecal delivery when other treatments fail.
An RNAi therapeutic targeting hepatic angiotensinogen, in trials for hypertension. A single dose may sustain blood pressure reduction for six months by blocking the RAAS cascade upstream.
Safety Information
Before engaging with any research on peptides, understand the foundational principles that guide safe, informed inquiry.
Always look for third-party Certificate of Analysis (CoA) documents confirming identity, purity ≥98%, and absence of contaminants like heavy metals or endotoxins.
Regulatory classification of peptides varies significantly by country. Many are legal only for research purposes and are not approved for human use. Know your jurisdiction.
Hormonal peptides can interact with existing medical conditions, other substances, and medications. Always review full contraindication profiles before research.
Research literature often uses a range of doses. Understanding minimum effective doses and starting conservatively reduces risk during experimental protocols.
Any exploration involving peptides should be discussed with a qualified healthcare provider who can monitor biomarkers and manage health risks.
Reputable research-grade suppliers should provide batch-specific CoAs, HPLC data, and mass spectrometry results. Never use compounds from unverified sources.
Peptide Blog
In-depth educational guides on 126+ peptides. Deep dives into mechanisms, research findings, and safety profiles.
Explore the science behind BPC-157's regenerative mechanisms, research findings in tissue repair, and safety profile.
Read Full Guide →A comprehensive look at semaglutide's mechanism, the landmark STEP and SELECT trial results, and clinical applications.
Read Full Guide →How tirzepatide's dual-agonist approach achieves unprecedented metabolic results in SURMOUNT and SURPASS trials.
Read Full Guide →Exploring the cognitive and neuroprotective properties of Semax, its BDNF modulation, and clinical research history.
Read Full Guide →The science behind Epithalon's potential effects on telomere length, melatonin production, and aging processes.
Read Full Guide →Understanding TB-500's role in tissue repair, cardiac recovery, and wound healing through actin regulation.
Read Full Guide →Get in Touch
Answers to the most common questions we receive.
Have a question, correction, or collaboration inquiry? We'd love to hear from you.